Latest filings (excl ownership)
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
19 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
6 Mar 24
8-K
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
1 Mar 24
EFFECT
Notice of effectiveness
14 Feb 24
424B7
Prospectus with selling stockholder info
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
S-3
Shelf registration
6 Feb 24
D
$6.00 mm in options / securities to be acquired, sold $6.00 mm, 6 investors
29 Jan 24
8-K
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
22 Jan 24
8-K
Entry into a Material Definitive Agreement
18 Jan 24
8-K
Talphera will begin trading on Nasdaq under the trading symbol “TLPH” effective January 10
9 Jan 24
EFFECT
Notice of effectiveness
1 Dec 23
CORRESP
Correspondence with SEC
29 Nov 23
UPLOAD
Letter from SEC
29 Nov 23
S-3
Shelf registration
22 Nov 23
S-8
Registration of securities for employees
22 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Oct 23
8-K
Departure of Directors or Certain Officers
10 Oct 23
DEFA14A
Additional proxy soliciting materials
5 Oct 23
8-K
Changes in Registrant's Certifying Accountant
5 Oct 23
8-K
Other Events
22 Sep 23
DEFA14A
Additional proxy soliciting materials
28 Aug 23
DEF 14A
Definitive proxy
28 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
EFFECT
Notice of effectiveness
10 Aug 23
424B7
Prospectus with selling stockholder info
9 Aug 23
CORRESP
Correspondence with SEC
7 Aug 23
UPLOAD
Letter from SEC
7 Aug 23
S-3
Shelf registration
2 Aug 23
8-K
Other Events
31 Jul 23
D
$10.00 mm in equity / options / securities to be acquired, sold $10.00 mm, 10 investors
28 Jul 23
8-K
Entry into a Material Definitive Agreement
21 Jul 23
8-K
Other Events
15 Jun 23
10-Q
2022 Q1
Quarterly report
10 May 23
8-K
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
10 May 23
Latest ownership filings
4
Wilmot B. Harkey
21 Mar 24
4
Wilmot B. Harkey
15 Mar 24
4
Vincent J. Angotti
12 Mar 24
4
Badri N Dasu
4 Mar 24
4
Pamela P Palmer
4 Mar 24
4
RAFFI ASADORIAN
4 Mar 24
4
Vincent J. Angotti
4 Mar 24
4
Pamela P Palmer
27 Feb 24
4
Badri N Dasu
27 Feb 24
4
RAFFI ASADORIAN
27 Feb 24
4
Vincent J. Angotti
27 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Badri N Dasu
13 Feb 24
4
Pamela P Palmer
13 Feb 24
4
RAFFI ASADORIAN
13 Feb 24
4
Vincent J. Angotti
13 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
Wilmot B. Harkey
24 Jan 24
4
ABHINAV JAIN
23 Jan 24
3
ABHINAV JAIN
23 Jan 24
SC 13D
Nantahala Capital Management, LLC
23 Jan 24
3
Wilmot B. Harkey
22 Jan 24
4
Vincent J. Angotti
14 Dec 23
4
STEPHEN J HOFFMAN
13 Dec 23
4
Richard Afable
13 Dec 23
4
MARK A WAN
13 Dec 23
4
Marina Bozilenko
13 Dec 23
4
Jill Marie Broadfoot
13 Dec 23
4
Howard B Rosen
13 Dec 23
4
ADRIAN ADAMS
13 Dec 23
4
Vincent J. Angotti
11 Sep 23
4
Pamela P Palmer
25 Aug 23
144
Notice of proposed sale of securities
25 Aug 23
144
Notice of proposed sale of securities
24 Aug 23
SC 13G
Lind Global Fund II LP
1 Aug 23
4
Badri N Dasu
6 Mar 23
4
Pamela P Palmer
6 Mar 23
4
RAFFI ASADORIAN
6 Mar 23
4
Vincent J. Angotti
6 Mar 23
4
Vincent J. Angotti
14 Feb 23